Xarelto Lawsuit Numbers Rise Above 3,400 In Louisiana MDL And Pennsylvania Mass Tort Program

April 01, 2016 – – BloodThinnerHelp.com reports on recent documented Xarelto lawsuit numbers, which show that complaints filed against defendants Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) discussing the new-generation blood-thinning drug they manufacture (Xarelto) have risen above 3,400 in number across the nation. This continually growing number is made up two main lawsuit groupings: a consolidation of more than 2,800 Xarelto lawsuits which were transferred to a single court by the U.S. JPML to form MDL number 2592 in the Eastern District of Louisiana, and a mass tort program comprised of more than 600 lawsuits which was formed by the Court of Common Pleas in Philadelphia, Pennsylvania.

The thousands of lawsuit plaintiffs all similarly allege that Janssen and Bayer have failed to adequately warn consumers and medical professionals concerning a potentially heightened risk of the occurrence of dangerous bleeding episodes among patients using the blood thinner.

Those currently awaiting trial dates have discovered support from the fact that their Xarelto allegations are very similar to thousands of previously settled lawsuits which were filed against the manufacturer of anticoagulant drug Pradaxa. The Pradaxa cases were settled by the the defendant (manufacturer Boehringer Ingelheim) the night before trials were set to begin.

Xarelto gained approval by the United States Food and Drug Administration in 2011 and launched onto the market as a revolutionary new type of blood thinner that could provide patients with increased freedoms that traditional blood thinners had not been able to. It was approved for treatment of patients recovering from hip and knee replacement surgeries, as well as patients suffering from pulmonary embolism, deep vein thrombosis, or atrial fibrillation.

Many who are closely connected to Xarelto lawsuits believe that filing numbers will only continue to increase as plaintiffs await 2017 bellwether trial dates. As time goes on, Attorney Joseph Osborne is working to help others who believe that they were negatively impacted by the drug. He wants to ensure that affected patients will be given the opportunity to fully explore their legal options in the matter. These individuals could be entitled to significant compensation attained through legal action. To help those interested, Attorney Osborne is offering free legal consultations for qualified parties at this time.

To request additional Xarelto lawsuit information, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009031